Group 1 - The company Anxing Zhenghe (Changsha) Biotechnology Co., Ltd. has been established with a registered capital of 5 million RMB [1] - The legal representative of the company is Yin Shan, and it is jointly held by Heyuan Biotechnology (Shanghai) Co., Ltd. (67% ownership) and Changsha Duozheng Medical Testing Co., Ltd. (33% ownership) [1] - The business scope includes the production and operation of various medical devices, drug import and export, and research and development in cell technology and human stem cell technology [1] Group 2 - The company is classified under the manufacturing industry, specifically in the pharmaceutical manufacturing sector [1] - The registered address of the company is located at 1058 Wenxuan Road, Lugu Street, Xiangjiang New District, Hunan [1] - The business license is valid until January 5, 2026, with no fixed expiration date [1]

南华生物公告称，公司于2025年8月12日披露拟现金收购程泽能等合计持有的慧泽医药51%股权，交易 完成后慧泽医药将成控股子公司。根据初步测算，本次交易预计构成重大资产重组，不构成关联交易， 不涉及发行股份，也不会导致控制权变更。截至公告披露日，针对慧泽医药的审计、评估等工作仍在进 行，相关方就核心条款谈判，尚未签署正式收购协议，交易实施存在不确定性。 ...

Group 1 - Fulin Precision's subsidiary plans to invest 6 billion yuan to build a high-end lithium iron phosphate project with an annual production capacity of 500,000 tons [11] - Feiwo Technology has completed the acquisition of 60% of Xinsai Aerospace, focusing on metal 3D printing services for commercial aerospace [2] - Zhongcai Technology expects a net profit increase of 73.79% to 118.64% in 2025 [30] Group 2 - Hengrui Medicine has received approval for clinical trials of HRS9531 injection in combination with HRS-5817 injection for treating obesity [2] - Deyun Co. announced that its actual controller has been arrested for illegal public deposit collection, but the company's operations remain normal [3] - Hengshi Technology's control is set to change as it enters a strategic cooperation agreement with New Base Information Technology Group [4] Group 3 - Zhejiang Mining plans to acquire 100% of Alaigyr Company, which holds core assets in lead-silver mines [5][6] - Guizhou Tire intends to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [7] - Dongfang Zircon plans to invest in a project to produce 10,000 tons of high-purity composite zircon oxide for new energy batteries [8] Group 4 - Xingsheng Group has received a project designation notice from a North American electric vehicle manufacturer, with a total sales amount of approximately 7.8 billion yuan [18] - Jin Di Co. plans to acquire a 3.36% stake in Baoshilai New Materials Technology for 21.6 million yuan [10] - Huayi Technology has signed a strategic cooperation agreement with Fujian Fuyou University to enhance research and development in alloy materials [6] Group 5 - Juxing Technology expects a net profit increase of 5% to 20% in 2025 [23] - Huayou Cobalt anticipates a net profit increase of 40.8% to 55.24% in 2025 [24] - Chifeng Gold expects a net profit increase of approximately 70% to 81% in 2025 [25]

Group 1 - The China Securities Association announced the first batch of companies for on-site inspection of IPO applications in 2026, consisting of 11 companies [1] - These companies submitted their applications at the end of 2025, with most being accepted in December [2] Group 2 - The companies and their key information are as follows: - Luoyang Bearing Group Co., Ltd.: Plans to list on the Growth Enterprise Market, focusing on bearings and related components, with projected 2024 revenue of 467.49 million and net profit of 17.95 million [3] - Precision Laser Technology Co., Ltd.: Plans to list on the Sci-Tech Innovation Board, specializing in laser products, with projected 2024 revenue of 29.19 million and net profit of 11.14 million [3] - Guangdong Yuxin Semiconductor Technology Co., Ltd.: Plans to list on the Growth Enterprise Market, focusing on specialty process wafer foundry, with projected 2024 revenue of 168.13 million and a net loss of 250.34 million [3] - Shenzhen Hanno Medical Technology Co., Ltd.: Plans to list on the Sci-Tech Innovation Board, specializing in ECMO systems, with projected 2024 revenue of 4.93 million and a net loss of 18.28 million [3] - Guangdong Jiuan Intelligent Technology Co., Ltd.: Plans to list on the Growth Enterprise Market, focusing on smart visual product manufacturing, with projected 2024 revenue of 779.69 million and net profit of 10.15 million [3] - Suzhou LQ Intelligent Equipment Co., Ltd.: Plans to list on the Growth Enterprise Market, focusing on high-end intelligent equipment manufacturing, with projected 2024 revenue of 542.93 million and net profit of 17.43 million [3] - Jiangsu Gaokai Precision Fluid Technology Co., Ltd.: Plans to list on the Sci-Tech Innovation Board, focusing on key control components in precision fluid control, with projected 2024 revenue of 423.17 million and net profit of 9.52 million [3] - Shanghai Taosheng Electronic Technology Co., Ltd.: Plans to list on the Sci-Tech Innovation Board, specializing in semiconductor testing interfaces, with projected 2024 revenue of 331.07 million and net profit of 1.14 million [3] - China Salt Industry Corporation: Plans to list on the Shanghai Main Board, focusing on edible salt and industrial salt, with projected 2024 revenue of 704.40 million and net profit of 28.80 million [3] - Ruishi Chuangxin (Chongqing) Technology Co., Ltd.: Plans to list on the Sci-Tech Innovation Board, focusing on RF front-end chips and modules, with projected 2024 revenue of 66.86 million and a net loss of 36.58 million [3] - Blue Arrow Aerospace Technology Co., Ltd.: Plans to list on the Sci-Tech Innovation Board, focusing on liquid oxygen-methane engines and launch vehicles, with projected 2024 revenue of 427.83 million and a net loss of 113.80 million [3]

天眼查显示，近日，扬州万虹中药材有限公司成立，法定代表人为赵智超，注册资本500万人民币，由 涉县以岭燕赵中药材有限公司全资持股。 序号股东名称持股比例1涉县以岭燕赵中药材有限公司100% 企业名称扬州万虹中药材有限公司法定代表人赵智超注册资本500万人民币国标行业制造业>医药制造 业>化学药品制剂制造地址宝应县射阳湖镇工业集中区企业类型有限责任公司（非自然人投资或控股的 法人独资）营业期限2026-1-4至无固定期限登记机关宝应县数据局 来源：市场资讯 经营范围含地产中草药（不含中药饮片）购销；中草药种植；中草药收购；食用农产品批发；食用农产 品零售；食用农产品初加工；非食用农产品初加工；农副产品销售；初级农产品收购；互联网销售（除 销售需要许可的商品）；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广（除依法须 经批准的项目外，凭营业执照依法自主开展经营活动） ...

Group 1 - Longjian Co., Ltd. reported a net profit of 405 million yuan for 2025, a decrease of 2.05% year-on-year, with operating revenue of 17.685 billion yuan, down 3.31% year-on-year, impacted by industry factors and national macro policies [1] - Dayang Bio's net profit for 2025 is expected to increase by 50.60% to 72.56%, reaching between 96 million and 110 million yuan, driven by strong performance in core products such as potassium carbonate and veterinary raw materials [2] - Dongcheng Pharmaceutical plans to repurchase shares worth between 100 million and 200 million yuan to implement equity incentives and/or employee stock ownership plans [3] Group 2 - Longpan Technology intends to invest up to 2 billion yuan in a high-performance lithium battery cathode material project, with a production capacity of 240,000 tons per year [4] - Jinggong Technology successfully launched its first carbon fiber precursor production line, which began trial production on December 31, 2025, and is now in continuous operation [5] - Shengxing Co. has decided to withdraw from the establishment of a life insurance company due to the lack of approval from regulatory authorities, which will not adversely affect its operations [6] Group 3 - ST Yigou's shareholder restructuring plan has been approved by the court, allowing the company to continue its operations without disruption [7] - Dream Network Technology has entered into a cooperation agreement with Jiangxi Shenzhou Liuhe to jointly develop and produce heavy-duty drone products, with a total development budget of 60 million yuan [8] - Haizheng Pharmaceutical's major shareholder, Zhejiang International Trade Group, plans to transfer 6.06% of its shares through a public solicitation, which will not change the company's controlling shareholder [10] Group 4 - Zhenhua Co. plans to issue convertible bonds to raise up to 878 million yuan for various projects, including a vitamin K3 production project and working capital [11] - Fangda Carbon has decided to terminate its participation in the substantive merger and restructuring of the Shanshan Group due to insufficient due diligence [12] - Xingqi Eye Medicine received approval for a supplementary application for atropine sulfate eye drops, expanding its product specifications [13] Group 5 - Shengyi Technology intends to invest 4.5 billion yuan in a high-performance copper-clad laminate project in Dongguan [14] - China Nuclear Power's Fujian Zhangzhou Nuclear Power Plant Unit 2 has completed its 168-hour full power continuous operation assessment and is ready for commercial operation, increasing the company's operational nuclear units to 27 [15] - Guangdong Electric Power A announced the phased shutdown of its ShaJiao C power plant, which will not affect the company's ongoing operations [16] Group 6 - Century Huatong plans to repurchase shares worth between 300 million and 600 million yuan for equity incentives or employee stock ownership plans [17] - Guoguang Electric's general manager has had his detention lifted and has returned to work, with normal operations resuming [19]

格隆汇1月4日丨中核科技(000777.SZ)公布，公司参股公司深圳市中核海得威生物科技有限公司（简 称"海得威"）近日补缴2021年1月1日至2024年12月31日企业所得税、增值税等税费1.88亿元及滞纳金， 合计约2.71亿元，主要涉及海得威前述年度期间的销售费用、存货非正常损失等事项，不涉及行政处 罚。海得威已完成该税费缴纳，预计上述事项将影响公司2025年度归母净利润约0.75亿元，实际以2025 年度经审计的财务报表为准。 ...

Core Insights - The "2025 Hainan Private Enterprises Top 100" and "2025 Hainan Private Enterprises R&D Investment Top 20" lists were released, showcasing the strong development capabilities of Hainan's private sector [3][4] - The total revenue of the top 100 private enterprises reached 346.79 billion yuan in 2024, with an average revenue of 3.468 billion yuan per enterprise, reflecting a year-on-year growth of 10.35% [3][4] - The R&D investment of the top 20 enterprises surpassed 4 billion yuan, reaching 4.166 billion yuan, with an average R&D intensity of 15.31%, indicating a robust commitment to innovation [4] Group 1: Top 100 Private Enterprises - The entry threshold for the top 100 private enterprises increased to 299 million yuan, with 6 companies reporting revenues exceeding 10 billion yuan [3][4] - The top 100 enterprises span 35 industries, with a significant presence in manufacturing, which accounts for 36% of the list, highlighting the sector's role as a core support for the real economy [3][4] Group 2: R&D Investment Top 20 - The entry threshold for the R&D investment top 20 reached 52.34 million yuan, with total R&D expenses growing by 10.71% year-on-year [4] - The top 20 enterprises demonstrated solid operational performance, with total assets and revenue increasing by 12.79% and 21.59% respectively [4] Group 3: Economic Contribution - In the first three quarters of the year, Hainan's private economy contributed 338.63 billion yuan, representing a year-on-year growth of 4.2%, accounting for nearly 60% of the province's GDP and over 90% of employment positions [4]

Investment Rating - The report indicates a recovery in the overall industry, with consumer goods leading the major categories [1] Core Insights - The national PMI for December is 50.1, reflecting a month-on-month increase of 0.9 percentage points and a year-on-year increase of 0, which is 1.4 percentage points higher than the recent average [1][3] - The production index has rebounded to 51.7, with a month-on-month increase of 1.7 percentage points, while the new orders index has risen to 50.8, up by 1.6 percentage points [4][9] - The highest absolute values among industries this month are in pharmaceuticals, clothing, transportation, and communication, while the highest month-on-month increases are seen in petroleum, clothing, and timber [1][3] Summary by Sections Manufacturing PMI - The manufacturing PMI index stands at 50.1, with 4 industries above 50 and 11 below [3] - The highest PMI is in the pharmaceutical manufacturing sector at 58.9, while the lowest is in general equipment manufacturing at 40.7 [3] New Orders Index - The new orders index is at 50.8, with 3 industries above 50 and 8 below [4] - The highest new orders index is also in pharmaceuticals at 62.5, while the lowest is in petroleum processing at 35.7 [5][6] Profit Trend Index - The profit trend index for manufacturing is -2.3, showing a month-on-month increase of 2.1 percentage points [7] - The highest profit trend index is in the automotive manufacturing sector at 9.3, while the lowest is in non-ferrous metal smelting at -25 [7][10] Production Index - The production index is at 51.7, with 5 industries above 50 and 9 below [9] - The highest production index is in the textile and apparel sector at 67.9, while the lowest is in general equipment manufacturing at 38.9 [9] Purchase Price Index - The purchase price index is at 53.1, down by 0.5 percentage points from last month [13] - The highest purchase price index is in non-ferrous metal smelting at 68.8, while the lowest is in petroleum processing at 32.1 [13][14] Finished Goods Inventory Index - The finished goods inventory index is at 48.2, with 4 industries above 50 and 10 below [17] - The highest inventory index is in pharmaceuticals at 55, while the lowest is in metal products at 31.3 [17] Export Orders Index - The export orders index is at 49, with 3 industries above 50 and 8 below [18] - The highest export orders index is in textiles at 62.5, while the lowest is in agricultural products at 33.3 [19][22]

Group 1 - The A-share merger and acquisition market remains active, with several companies announcing significant developments on December 30 [1] - Zhongneng Electric announced the termination of its plan to acquire 65% of Shandong Dachai Electric Co., Ltd. and related debts [2][4] - Dongjie Intelligent also decided to terminate its plan to acquire the controlling stake in Aobo (Beijing) Intelligent Technology Co., Ltd. [4] Group 2 - Mingde Biological announced a cash acquisition of 100% equity in Wuhan Bikaier Rescue Supplies Co., Ltd., which is expected to constitute a significant asset restructuring [5][7] - The transaction is in the preliminary planning stage and will not involve share issuance or change in control of the company [7] - Mingde Biological aims to focus on the critical care business segment through this acquisition, as the target company specializes in emergency rescue products and services [7] Group 3 - Yanhai Co. plans to acquire 51% of Wenkang Yanhai Co., Ltd. for 4.605 billion yuan, making it a subsidiary post-transaction [1] - Shengxin Lithium Energy intends to acquire 30% of Sichuan Qicheng Mining Co., Ltd. for 2.08 billion yuan, resulting in full ownership after the deal [1]